ClinicalTrials.gg
RecruitingNCT07936045Updated Nov 13, 2026

Anterior Versus Posterior Surgery for Eyelid Ptosis

An interventional study of Anterior levator aponeurosis advancement and Posterior levator aponeurosis advancement in Ptosis, Eyelid, sponsored by Hospital Universitario 12 de Octubre. Recruiting at 1 site in Spain. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Hospital Universitario 12 de Octubre · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Jun 2026, registered Oct 2026).
  • Started Jun 2026; still recruiting 5 months later.
Updated Nov 13, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Sex
All
01

Study summary

The goal of this randomized clinical trial is to compare two surgical approaches for correcting drooping of the upper eyelid (aponeurotic ptosis) in adults who need surgery. This condition occurs when the tissue connecting the eyelid-lifting muscle to the eyelid becomes weakened or detached. It can affect one or both eyes.

The main questions this study aims to answer are:

  • Does surgery performed through the inner surface of the eyelid (posterior approach) achieve an upper eyelid height at 6 months that is not meaningfully worse than surgery performed through the skin (anterior approach)?
  • How do the two approaches compare in terms of complications, operating time, swelling, bruising, eyelid appearance, and patient satisfaction?
  • How stable are the results during the 6 months after surgery?

Researchers will compare anterior and posterior approaches to levator aponeurosis advancement, a procedure that repositions and reattaches the tissue connecting the eyelid-lifting muscle to the eyelid. Both approaches are routinely used at Hospital Universitario 12 de Octubre in Madrid, Spain, where the study will take place.

Participants will be assigned by chance to one of the two surgical groups, with an equal chance of receiving either approach. All procedures will be performed under local anesthesia by the same experienced surgeon.

The main outcome is upper eyelid height 6 months after surgery, measured as the distance between the upper eyelid edge and the reflection of a light at the center of the pupil. The study will assess whether the posterior approach is no more than 0.5 millimeters worse than the anterior approach for this measurement. An independent healthcare professional will measure eyelid height and assess eyelid appearance.

Participants will:

  • Attend a preoperative assessment, including an eye examination and measurements of eyelid position and movement.
  • Undergo surgery using the randomly assigned approach.
  • Attend follow-up visits the day after surgery, at 1 week, and at 1, 3, and 6 months.
  • Have eyelid measurements and standardized photographs taken, and be assessed for swelling, bruising, and complications.
  • Answer questions about their satisfaction with the appearance and function of their eyelids at 1, 3, and 6 months.

The visits and clinical assessments follow the hospital's usual care schedule for this surgery. Participation does not require additional visits or invasive tests beyond routine care.

Read the detailed description

Scientific Rationale

Anterior and posterior approaches to levator aponeurosis advancement differ in the tissues accessed and the surgical exposure required to restore eyelid position. The anterior approach provides access through the skin and orbicularis muscle, whereas the posterior approach accesses the levator aponeurosis through the conjunctival surface. These differences may influence surgical duration, tissue trauma, postoperative recovery, and cosmetic results.

Although both approaches are established surgical options, direct prospective randomized comparisons remain limited. Evidence supporting posterior advancement includes surgical case series, while the anterior approach remains widely used. A randomized comparison may help clarify whether the posterior approach preserves functional effectiveness while offering advantages in recovery or other aspects of the surgical outcome.

Study Hypothesis and Methodological Rationale

The study uses a noninferiority framework for its primary efficacy comparison. This framework addresses whether posterior advancement maintains an acceptable functional result relative to anterior advancement, rather than requiring it to produce a greater postoperative eyelid height. Potential advantages in operative duration, postoperative tissue response, safety, and patient experience will be examined separately through secondary comparisons.

The allocation sequence will be computer-generated using randomly varying block sizes of four and six. A study team member who is not involved in performing the operations will generate the sequence. Variable block sizes are intended to maintain balance between groups during recruitment while reducing the predictability of subsequent assignments.

Using one surgeon experienced in both techniques is intended to limit variation attributable to differences in surgical experience. The surgeon cannot be masked to the assigned approach. An independent healthcare professional will perform the principal efficacy measurements and cosmetic assessments.

Statistical Analysis

Descriptive analyses will characterize the study population and summarize the data. Continuous variables will be reported as means and standard deviations or medians and interquartile ranges, as appropriate. Categorical variables will be reported as frequencies and percentages. The distribution of continuous variables will be assessed using the Shapiro-Wilk test.

The primary comparison will use analysis of covariance, with postoperative upper eyelid height at the primary assessment as the dependent variable, surgical approach as the group factor, and the corresponding preoperative measurement as a covariate. The treatment difference will be calculated as posterior minus anterior approach. Noninferiority will be established if the lower bound of the two-sided 95% confidence interval for the adjusted mean difference is greater than -0.5 mm. This corresponds to a one-sided significance level of 0.025.

Secondary continuous variables will be compared using an independent-samples Student's t-test or the Mann-Whitney U test, according to their distribution. Categorical variables will be compared using the chi-square test or Fisher's exact test, as appropriate. Changes in eyelid height over follow-up will be examined using repeated-measures analysis of variance or a linear mixed-effects model. Secondary comparisons will use a significance threshold of 0.05.

The primary noninferiority conclusion will be considered separately from the secondary comparisons. Demonstrating noninferiority in eyelid height alone will not be interpreted as evidence of superiority in safety, recovery, or cosmetic outcomes.

02

Conditions studied

  • Ptosis, Eyelid

Browse trials for

Keywords

  • ptosis
  • Aponeurotic ptosis
  • Blepharoptosis
  • Levator aponeurosis advancement
  • Posterior levator advancement
  • Transconjunctival approach
  • White-line advancement
  • Oculoplastic surgery
03

In context

Blepharoptosis

76 studies on the registry are indexed under Blepharoptosis; 15 are open to participants now.

This study's planned enrollment of 60 is above the median of 50 across 57 interventional studies indexed under Blepharoptosis.

Browse Blepharoptosis studies →

Lead sponsor

Hospital Universitario 12 de Octubre is the lead sponsor of 35 studies on the registry; 17 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults older than 18 years.
  • Diagnosis of unilateral or bilateral aponeurotic ptosis caused by weakening or disinsertion of the levator aponeurosis.
  • Clinical indication for surgical correction of ptosis.
  • No previous ocular surgery.
  • No other ophthalmic conditions that may affect eyelid anatomy.
  • Provision of written .

Exclusion criteria

Exclusion Criteria:

  • Congenital, traumatic, neurogenic, myogenic, or mechanical ptosis.
  • Previous eyelid surgery.
  • Inability to provide or refusal to participate.
  • Inability to cooperate with the surgical procedure under local anesthesia because of cognitive impairment or another disabling condition.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    Anterior levator aponeurosis advancement

    Participants assigned to this arm will undergo levator aponeurosis advancement and reattachment through an anterior (transcutaneous) approach, accessing the aponeurosis through the eyelid skin and orbicularis muscle. Surgery will be performed under local anesthesia by an experienced surgeon. This arm serves as the active comparator. Participants will receive routine postoperative care and follow-up for 6 months.

    Procedure: Anterior levator aponeurosis advancement

  • Experimental
    Posterior levator aponeurosis advancement

    Participants assigned to this arm will undergo levator aponeurosis advancement and reattachment through a posterior (transconjunctival) approach, accessing the aponeurosis through the inner surface of the eyelid. Surgery will be performed under local anesthesia by the same experienced surgeon. This arm will be evaluated for noninferiority to the anterior approach. Participants will receive routine postoperative care and follow-up for 6 months.

    Procedure: Posterior levator aponeurosis advancement

Interventions

  • ProcedureAnterior levator aponeurosis advancement

    Surgical correction of aponeurotic ptosis by advancement and reattachment of the levator aponeurosis through an anterior transcutaneous approach. The aponeurosis is accessed through the upper eyelid skin and orbicularis muscle to restore upper eyelid height. The procedure is performed under local anesthesia by a surgeon experienced in both study techniques.

  • ProcedurePosterior levator aponeurosis advancement

    Surgical correction of aponeurotic ptosis by advancement and reattachment of the levator aponeurosis through a posterior transconjunctival approach (white-line advancement). The aponeurosis is accessed through the inner surface of the upper eyelid to restore upper eyelid height. The procedure is performed under local anesthesia by the same surgeon performing the anterior approach.

06

What researchers measure

Primary outcomes

  1. Margin Reflex Distance 1 (MRD1) at 6 Months After Surgery

    Upper eyelid height assessed using margin reflex distance 1 (MRD1), defined as the vertical distance in millimeters between the upper eyelid margin and the corneal light reflex in primary gaze. Measurements will be performed by an independent healthcare professional. MRD1 at 6 months will be compared between the posterior and anterior levator aponeurosis advancement groups to assess noninferiority of the posterior approach.

    Time frame: 6 months after surgery

Secondary outcomes

  1. Number of Participants With Postoperative Complications

    Number of participants experiencing at least one postoperative complication during the 6-month follow-up period. Complications include infection, bleeding, corneal abnormalities, and wound or suture dehiscence. The type of complication will also be recorded. The proportion of participants with complications will be compared between the two surgical groups.

    Time frame: Complications From surgery through 6 months after surgery

  2. Surgical Duration

    Duration of the surgical procedure, measured in minutes. For the anterior approach, surgical time is measured from the skin incision to the start of skin closure. For the posterior approach, surgical time is measured from the transconjunctival incision to placement of the final fixation suture. Surgical duration will be compared between groups.

    Time frame: During surgery

  3. Postoperative Eyelid Edema Score

    Postoperative eyelid swelling assessed using the edema component of the Surgeon Periorbital Rating of Edema and Ecchymosis (SPREE) scale, as specified in the study protocol. The four grades range from 1 (no coverage of the iris by swollen eyelids) to 4 (complete eye closure due to swelling). Higher scores indicate greater edema. Scores will be recorded separately for each assessed side and compared between surgical groups.

    Time frame: 1 day and 1 week after surgery

  4. Postoperative Periorbital Ecchymosis Score

    Postoperative bruising assessed using the ecchymosis component of the Surgeon Periorbital Rating of Edema and Ecchymosis (SPREE) scale, as specified in the study protocol. Scores range from 0 (no ecchymosis) to 3 (ecchymosis extending over more than two-thirds of the eyelid length). Higher scores indicate more extensive bruising. Scores will be recorded separately for each assessed side and compared between surgical groups.

    Time frame: 1 day and 1 week after surgery

  5. Cosmetic Outcome Assessed by an Independent Healthcare Professional

    Postoperative eyelid appearance assessed by an independent healthcare professional using the study-specific cosmetic rating scale. Scores range from 0 to 10 and will be recorded at each scheduled cosmetic assessment. Cosmetic scores will be compared between the two surgical groups.

    Time frame: 1, 3, and 6 months after surgery

  6. Patient Satisfaction With Surgical Outcomes

    Overall patient satisfaction with ptosis surgery assessed using the five-point question in the study-specific patient questionnaire. Responses are scored as 1 (very dissatisfied), 2 (dissatisfied), 3 (neutral), 4 (satisfied), or 5 (very satisfied). Higher scores indicate greater satisfaction. Participants may also select reasons for satisfaction or dissatisfaction, including appearance, eyelid function, and postoperative symptoms. Overall satisfaction scores will be compared between surgical groups.

    Time frame: 1, 3, and 6 months after surgery

  7. Change From Baseline in Margin Reflex Distance 1 (MRD1) at 6 Months

    Change in upper eyelid height calculated as MRD1 at 6 months after surgery minus preoperative MRD1, measured in millimeters. MRD1 is the vertical distance between the upper eyelid margin and the corneal light reflex in primary gaze. A positive change indicates an increase in upper eyelid height relative to baseline. The change will be compared between the two surgical groups.

    Time frame: Before surgery and 6 months after surgery

  8. Margin Reflex Distance 1 (MRD1) Over Follow-up

    Repeated measurements of margin reflex distance 1 (MRD1), in millimeters, used to assess the evolution and stability of upper eyelid position after surgery. MRD1 is the vertical distance between the upper eyelid margin and the corneal light reflex in primary gaze. Measurements obtained at each follow-up visit will be performed by an independent healthcare professional and compared between the posterior and anterior levator aponeurosis advancement groups.

    Time frame: 1 day, 1 week, 1 month, 3 months, and 6 months after surgery

  9. Palpebral Fissure Height

    Vertical distance between the upper and lower eyelid margins, measured in millimeters in primary gaze. Measurements will be obtained before surgery and at the scheduled postoperative visits to characterize changes in eyelid opening. Palpebral fissure height will be compared between the two surgical groups.

    Time frame: Before surgery and at 1 day, 1 week, and 1, 3, and 6 months after surgery

07

Study locations

1 of 1 sites recruiting
  • Hospital Universitario 12 de Octubre
    Madrid, Madrid 28041, Spain
    Recruiting
    • Consuelo Mata Beltran, Medical Doctor · Contactchelomata00@gmail.com · +34 609443271
    • Silvia Perez Trigo, Medical Doctor · Contactconsuelo.mata@salud.madrid.org · +34 91 390 80 00
    • Consuelo Mata Beltran, M.D. · Principal investigator
    • Silvia Perez Trigo, M.D. P.H.D. · Sub investigator
    • Regina Lopez-Ladron Garcia-Borbolla, M.D · Sub investigator
    • Alvaro Bengoa Gónzalez, M.D. P.H.D. · Sub investigator
08

References and documents

Individual participant data

Plan to share: No — There is no current plan to share individual participant data. Study findings will be disseminated as aggregate results through peer-reviewed publications and scientific presentations.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Jan 2027, 7 months after the start.

Of 25 interventional studies with no phase under Blepharoptosis, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 57. This study's planned 7 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 30, 2026
First posted
Nov 13, 2026
StartActual
Jun 1, 2026
Primary completionEst.
Jan 31, 2027
CompletionEst.
Mar 31, 2027
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07936045
Lead sponsor
Hospital Universitario 12 de Octubre
Responsible party
Consuelo Mata Beltrán (Principal Investigator, Hospital Universitario 12 de Octubre) — Principal investigator
First posted
Nov 13, 2026
Start date
Jun 1, 2026
Primary completion
Jan 31, 2027 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Nov 13, 2026

Study contacts

Consuelo Mata Beltran, M.D.
Contact
chelomata00@gmail.com
+34 609443271
Silvia Perez Trigo, M.D P.H.D
Contact
consuelo.mata@salud.madrid.org
+34 91 390 80 00

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion